David Krupa

2.3k citations

51 papers · 1.7k indexed · h-index 24

Impact in

Endocrine and Autonomic Systems top 1%
- Regulation of Appetite and Obesity
Endocrinology, Diabetes and Metabolism top 2%
- Growth Hormone and Insulin-like Growth Factors
- Pituitary Gland Disorders and Treatments

Papers in

Endocrinology, Diabetes and Metabolism 20
- Growth Hormone and Insulin-like Growth Factors 17
- Adrenal Hormones and Disorders 5
Dermatology 9
- Dermatology and Skin Diseases 9

Co-authors: B. J. Gertz K. Cerchio Mark A. Bach R. A. Dybas Suzan S. Pezzoli Michael O. Thorner Johanna Wittreich R G Smith
Journals: The Journal of Clinical Endocrinology & Metabolism (9 papers)Pain Medicine (3 papers)Journal of Economic Entomology (3 papers)Current Medical Research and Opinion (3 papers)Journal of Endocrinology (3 papers)
Partner nations: United States Canada Sweden

In The Last Decade

David Krupa

49 papers receiving 1.6k citations

Peers

Countries citing papers authored by David Krupa

Since Specialization

Citations

This map shows the geographic impact of David Krupa's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Krupa with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Krupa more than expected).

Fields of papers citing papers by David Krupa

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Krupa. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Krupa. The network helps show where David Krupa may publish in the future.

Co-authors

The 25 scholars most cited alongside David Krupa, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with David Krupa Line = papers co-authored together David Krupa links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Long-Term Safety and Efficacy with Roflumilast Cream 0.15% in Patients Aged ≥6 Years with Atopic Dermatitis: A Phase 3 Open-Label Extension Trial Dermatitis ·Eric L. Simpson, Lawrence F. Eichenfield, Kim Papp, Seth Forman, Adelaide A. Hebert, Mercedes E. González, Melinda Gooderham, Hwanhee Hong, Vimal H. Prajapati, Emma Guttman‐Yassky, Jonathan I. Silverberg, Melissa S. Seal, David Krupa, Erin Almaraz, Diane Hanna, Patrick Burnett, S. Snyder, David H. Chu, Robert Higham, David R. Berk	2025	1
2	Efficacy and Safety of Once‐Daily Roflumilast Cream 0.05% in Pediatric Patients Aged 2–5 Years With Mild‐to‐Moderate Atopic Dermatitis ( INTEGUMENT ‐ PED ): A Phase 3 Randomized Controlled Trial Pediatric Dermatology ·Lawrence F. Eichenfield, Rocco Serrao, Vimal H. Prajapati, Joseph Browning, Lisa Swanson, Tracy Funk, Mercedes E. González, Adelaide A. Hebert, Mark S. Lee, Mark Boguniewicz, Eric L. Simpson, Melissa S. Seal, David Krupa, Diane Hanna, Scott Snyder, Patrick Burnett, David H. Chu, Robert Higham, David R. Berk	2025	3
3	53863 Pooled efficacy, patient-reported outcomes, and safety of roflumilast cream 0.15% from the INTEGUMENT-1 and INTEGUMENT-2 phase 3 clinical trials of adults and children with atopic dermatitis Journal of the American Academy of Dermatology ·Eric L. Simpson, Mark Boguniewicz, Lawrence F. Eichenfield, Mercedes E. Gonzales, Adelaide A. Hebert, Vimal H. Prajapati, Melinda Gooderham, David Krupa, David H. Chu, Robert Higham, David R. Berk	2024	0
4	Durability of Efficacy and Safety of Roflumilast Cream 0.3% in Adults With Chronic Plaque Psoriasis From a 52-Week, Phase 2 Open-Label Safety Trial SKIN The Journal of Cutaneous Medicine ·Mark Lebwohl, Linda Stein Gold, Melinda Gooderham, Kim Papp, Laura K. Ferris, David Adam, Hwanhee Hong, Leon Kircik, Matthew Zirwas, Patrick Burnett, Robert Higham, David Krupa, David R. Berk	2023	1
5	390 Efficacy and safety of roflumilast cream 0.15% in adults and children aged ≥6 years with mild to moderate atopic dermatitis in two phase 3 trials (INTEGUMENT-1 and INTEGUMENT-2) British Journal of Dermatology ·Eric L. Simpson, Lawrence F. Eichenfield, Melinda Gooderham, Mercedes E. González, Adelaide A. Hebert, Kim Papp, Vimal H. Prajapati, David Krupa, Patrick Burnett, David R. Berk, Robert Higham	2023	1
6	Efficacy and Safety of Roflumilast Foam 0.3% in Patients With Seborrheic Dermatitis in a Phase 3 Trial SKIN The Journal of Cutaneous Medicine ·Andrew Blauvelt, Javier Alonso‐Llamazares, Neal Bhatia, Zoé Kececioglu Draelos, Janet DuBois, Seth Forman, Melinda Gooderham, Scott Guenthner, Adelaide A. Hebert, Edward Lain, Angela Moore, Kim Papp, Linda Stein Gold, Matthew Zirwas, Saori Kato, Scott Snyder, David Krupa, Patrick Burnett, David R. Berk, David Chu	2023	0
7	Sequential administration of Prevnar 13™ and PNEUMOVAX™ 23 in healthy participants 50 years of age and older Human Vaccines & Immunotherapeutics ·Ulrike K. Buchwald, Charles P. Andrews, John Ervin, James T. Peterson, Gretchen Tamms, David Krupa, Patrick Ajiboye, Lucy Roalfe, Andrea Likos Krick, Tina M. Sterling, Meihua Wang, Jason Martin, Jon E. Stek, Melvin A. Kohn, Temitope Folaranmi, Chitrananda Abeygunawardana, Jonathan Hartzel, Luwy Musey, (unknown)	2021	10
8	The Time to Onset and Overall Analgesic Efficacy of Rofecoxib 50 mg Clinical Journal of Pain ·Paul J. Desjardins, Donald R. Mehlisch, David J. Chang, David Krupa, Adam B. Polis, Richard A. Petruschke, Kerstin Malmström, Gregory P. Geba	2005	13
9	Use of gastroprotective agents and discontinuations due to dyspepsia with the selective cyclooxygenase-2 inhibitor etoricoxib compared with non-selective NSAIDs* Current Medical Research and Opinion ·D.J. Watson, James A. Bolognese, Chang Yu, David Krupa, Sean Curtis	2004	15
10	Onset of pain relief with rofecoxib in chronic low back pain: results of two four-week, randomized, placebo-controlled trials Current Medical Research and Opinion ·Nathaniel P. Katz, Diana Bozalis Rodgers, David Krupa, Alise Reicin	2004	20
11	Efficacy and Safety of Rofecoxib in Patients with Chronic Low Back Pain Spine ·Nathaniel P. Katz, William D. Ju, David Krupa, Rhoda Sperling, Diana Bozalis Rodgers, Barry J. Gertz, Joseph Gimbel, Spencer Coleman, Chester Fisher, Shahriar Nabizadeh, David Borenstein	2003	45
12	Spine ·Nathaniel P. Katz, William Ju, David Krupa, Rhoda Sperling, Diana Bozalis Rodgers, Barry J. Gertz, Joseph Gimbel, Spencer Coleman, Chester F. Fisher, Shahriar Nabizadeh, David Borenstein, the Vioxx Chronic Low Back Pain Study Group	2003	1
13	Efficacy of single-dose and multidose rofecoxib in the treatment of post-orthopedic surgery pain. PubMed ·Alise Reicin, Jessica Brown, M Jove, J R deAndrade, Michael H. Bourne, David Krupa, Dustin M. Walters, Beth C. Seidenberg	2001	67
14	Effect of Alendronate and MK-677 (a Growth Hormone Secretagogue), Individually and in Combination, on Markers of Bone Turnover and Bone Mineral Density in Postmenopausal Osteoporotic Women¹ The Journal of Clinical Endocrinology & Metabolism ·M. Gail Murphy, (unknown), Michael R. McClung, Thomas J. Schnitzer, K. Cerchio, Jennie Connor, David Krupa, B. J. Gertz	2001	67
15	Alendronate in Early Postmenopausal Women: Effects on Bone Mass during Long-Term Treatment and after Withdrawal¹ The Journal of Clinical Endocrinology & Metabolism ·Pernille Ravn, Stuart Weiss, Jose Adolfo Rodriguez-Portales, Michael R. McClung, Richard D. Wasnich, Nigel Gilchrist, Philip N. Sambrook, Ignac Fogelman, David Krupa, A.J.P. Yates, Anastasia G. Daifotis, Ghada El‐Hajj Fuleihan	2000	84
16	Oral Administration of the Growth Hormone Secretagogue MK-677 Increases Markers of Bone Turnover in Healthy and Functionally Impaired Elderly Adults Journal of Bone and Mineral Research ·M. Gail Murphy, Mark A. Bach, D. Plotkin, JA Bolognese, Jennifer Ng, David Krupa, K. Cerchio, B. J. Gertz	1999	39
17	Two-Month Treatment of Obese Subjects with the Oral Growth Hormone (GH) Secretagogue MK-677 Increases GH Secretion, Fat-Free Mass, and Energy Expenditure¹ The Journal of Clinical Endocrinology & Metabolism ·Johan Svensson, Lars Lönn, John‐Olov Jansson, Gail Murphy, Daniel F. Wyss, David Krupa, K. Cerchio, William J. Polvino, B. Gertz, I. Boseaus, Lars Sjöström, B.‐Å. Bengtsson	1998	125
18	Oral Administration of Growth Hormone (GH) Releasing Peptide-Mimetic MK-677 Stimulates the GH/Insulin-Like Growth Factor-I Axis in Selected GH-Deficient Adults¹ The Journal of Clinical Endocrinology & Metabolism ·Ian Chapman, Ora Hirsch Pescovitz, Gail Murphy, Theresa Treep, K. Cerchio, David Krupa, Barry J. Gertz, William J. Polvino, Emily H. Skiles, Suzan S. Pezzoli, Michael O. Thorner	1997	49
19	Effect of Obesity and Feeding on the Growth Hormone (GH) Response to the GH Secretagogue L-692,429 in Young Men¹ The Journal of Clinical Endocrinology & Metabolism ·Susan E. Kirk, Barry J. Gertz, Stephen H. Schneider, Mark L. Hartman, Suzan S. Pezzoli, Johanna Wittreich, David Krupa, James R. Seibold, Michael O. Thorner	1997	17
20	Repeat administration of the GH secretagogue MK-0677 increases and maintains elevated IGF-I levels in beagles Journal of Endocrinology ·Gerard J. Hickey, Thomas M. Jacks, Klaus D. Schleim, Easter G. Frazier, H Y Chen, David Krupa, William P. Feeney, Ravi P. Nargund, Arthur A. Patchett, R G Smith	1997	38

About David Krupa

David Krupa is a scholar working on Endocrinology, Diabetes and Metabolism, Dermatology, Pharmacology, Immunology and Allergy and Physiology, having authored 51 papers that have together received 1.7k indexed citations. Recurring topics across this work include Growth Hormone and Insulin-like Growth Factors (17 papers), Inflammatory mediators and NSAID effects (11 papers), Dermatology and Skin Diseases (9 papers), Asthma and respiratory diseases (6 papers), Adrenal Hormones and Disorders (5 papers), Neuropeptides and Animal Physiology (5 papers), Psoriasis: Treatment and Pathogenesis (5 papers) and Diabetes and associated disorders (4 papers). The work is most often cited by research in Endocrine and Autonomic Systems (551 citations), Endocrinology, Diabetes and Metabolism (742 citations), Physiology (495 citations), Urology (109 citations) and Pharmacology (249 citations). David Krupa has collaborated with scholars based in United States, Canada and Sweden. Frequent co-authors include B. J. Gertz, K. Cerchio, Mark A. Bach, R. A. Dybas, Suzan S. Pezzoli, Michael O. Thorner, Johanna Wittreich, R G Smith, Gerard J. Hickey and Mark L. Hartman. Their work appears in journals such as The Journal of Clinical Endocrinology & Metabolism, Pain Medicine, Journal of Economic Entomology, Current Medical Research and Opinion and Journal of Endocrinology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact